¼¼°èÀÇ ·¹³ì½º °¡½ºÅä ÁõÈıº(LGS) Ä¡·áÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Lennox-Gastaut Syndrome Drug Global Market Report 2025
»óǰÄÚµå : 1760590
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

·¹³ì½º °¡½ºÅä ÁõÈıº(LGS) Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº Á¤¹Ð ÀÇÇп¡ ´ëÇÑ °­Á¶ Áõ°¡, ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó È®Àå, ÀÓ»ó ½ÃÇè °Ç¼ö Áõ°¡, °³¼±µÈ º¸Çè »óȯ Á¤Ã¥, Èñ±Í Áúȯ ¿¬±¸ °³¹ß ÅõÀÚ Áõ´ë, ±×¸®°í À¯ÀüÀÚ °Ë»ç¸¦ ÅëÇÑ Áø´ÜÀ² »ó½Â°ú °°Àº ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£¿¡ À־ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î¼­´Â Áø´Ü ±â¼úÀÇ Çõ½Å, µå·¯±× µô¸®¹ö¸® ±â¼úÀÇ ¹ßÀü, ¹ÙÀÌ¿À¸¶Ä¿ µ¿Á¤ÀÇ ÁøÀü, ½Å¾à¿¡ À־ÀÇ ÀΰøÁö´ÉÀÇ È°¿ë, Â÷¼¼´ë ½ÃÄö¼­ ±â¼úÀÇ °³¹ß, Ç¥Àû À¯ÀüÀÚ Ä¡·áÀÇ Ã¢Ãâ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¼Ò¾Æ °£ÁúÀ» Áß½ÃÇÏ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖ¾î ÇâÈÄ ¼ö³â°£¿¡ ·¹³ì½º °¡½ºÅä ÁõÈıº(LGS) Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ²ø¾î ¿Ã °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼Ò¾Æ ³úÀüÁõÀº ½Å»ý¾Æ ¹× À¯¾Æ ³ú ¼Õ»óÀÇ Áõ°¡À²·Î ÀÎÇØ À¯º´·üÀÌ Áõ°¡ÇÏ´Â µî ¾î¸°ÀÌ¿¡°Ô ¹Ýº¹ÀûÀÎ ¹ßÀÛÀÌ ³ªÅ¸³ª´Â ½Å°æÇÐÀû ÁúȯÀ¸·Î, À¯¾Æ±â¿¡ ³úÀüÁõÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. °£ÁúÀ» °¡Áø ¼Ò¾ÆÀÇ ¹ß´Þ Áöü¸¦ ¸·±â À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. 2022³â¿¡ 18¼¼ ÀÌ»óÀÇ ¹Ì±¹ ¼ºÀÎ ¾à 290¸¸¸íÀÌ È°µ¿¼º °£ÁúÀ» ¾Î°í, ¹Ì±¹ÀÇ ¼ºÀÎ Àα¸ÀÇ ¾à 1%¸¦ Â÷ÁöÇÑ´Ù°í º¸°íÇß½À´Ï´Ù.

·¹³ì½º °¡½ºÅä ÁõÈıº(LGS) Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ±ÔÁ¦ ´ç±¹ÀÇ ÁöÁö¸¦ ¾ò°í ½ÃÀå µ¶Á¡±ÇÀ» È®º¸ÇϸçÀÌ Èñ±ÍÇÏ°í ½É°¢ÇÑ Áúº´¿¡ ´ëÇÑ Ä¡·áÀÇ »ó¾÷È­¸¦ ÃËÁøÇϱâ À§ÇØ Èñ±Í Áúº´ ÀǾàǰ ÁöÁ¤ÀÇ ÁøÀü¿¡ Á¡Á¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Èñ¼ÒÁúȯ¿ë ÀǾàǰÀÇ ÁöÁ¤Àº ƯÁ¤ Áö¿ª¿¡¼­ 20¸¸¸í ¹Ì¸¸¸¸À» ¾Î°í ÀÖ´Â Èñ¼ÒÁúȯÀ̳ª ÁúȯÀ» À§ÇØ °³¹ßµÈ ÀǾàǰ¿¡ FDA µîÀÇ ±ÔÁ¦ ´ç±¹ÀÌ ºÎ¿©Çϴ Ưº°ÇÑ »óÅÂÀÔ´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ Á¦¾àȸ»ç ¸¶¸®³ª½º ÆÛ¸Ó½´Æ¼ÄÃÁî À×Å©´Â 2023³â 3¿ù ·¹³ì½º °¡½ºÆ® ÁõÈıº(LGS) Ä¡·áÁ¦·Î °¡³«¼Ö·Ð¿¡°Ô FDA·ÎºÎÅÍ Èñ¼ÒÁúº´¿ë ÀǾàǰ ÁöÁ¤(ODD)À» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. LGS´Â ¼Ò¾Æ±â¿¡ ¹ßº´ÇÏ¿© ³­Ä¡¼º °£Áú ¹ßÀÛ°ú ½Å°æ ¹ß´Þ Àå¾Ö¸¦ Ư¡À¸·Î ÇÏ´Â ½É°¢ÇÑ °£ÁúÀÔ´Ï´Ù. ÀÌ ÁöÁ¤Àº ½ÂÀÎ ÈÄ ½ÃÀå µ¶Á¡±Ç, FDA ½Åû ºñ¿ë ¸éÁ¦, Àû°ÝÇÑ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ¼¼¾× °øÁ¦ µîÀÇ ÀÌÁ¡À» Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀåÀÇ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À: ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï ¹× °ü¼¼, Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔ

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå : °æÀï º¥Ä¡¸¶Å· ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ±â¾÷ ÇÕº´ ¹× Àμö(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡¡¤ºÎ¹®°ú Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Lennox-Gastaut syndrome drug refers to medication specifically developed or prescribed to manage the seizures and other symptoms associated with this severe form of epilepsy. These medications work by adjusting brain chemistry to control irregular electrical activity, thus reducing the frequency and severity of seizures.

The main types of Lennox-Gastaut syndrome drugs include central nervous system depressants, anticonvulsants, perampanel, cannabidiol, neural regeneration peptide 2945, and others. Central nervous system depressants are drugs that lower brain activity, helping with seizure control and promoting relaxation. They can be administered orally, via injection, intranasally, or topically, and are used for long-term management, acute seizure treatment, adjunctive therapy, and as rescue medications. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used in settings such as hospitals, clinics, home care, specialized epilepsy centers, and pharmaceutical retail outlets.

The lennox-gastaut syndrome drug market research report is one of a series of new reports from The Business Research Company that provides lennox-gastaut syndrome drug market statistics, including lennox-gastaut syndrome drug industry global market size, regional shares, competitors with an lennox-gastaut syndrome drug market share, detailed lennox-gastaut syndrome drug market segments, market trends and opportunities, and any further data you may need to thrive in the lennox-gastaut syndrome drug industry. The lennox-gastaut syndrome drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lennox-gastaut syndrome drug market size has grown strongly in recent years. It will grow from $1.30 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be credited to a rise in awareness of rare epileptic disorders, an increasing prevalence of pediatric epilepsy, better access to healthcare, enhanced investment in neurology research, and incentives provided by orphan drug designations.

The lennox-gastaut syndrome drug market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to a greater emphasis on precision medicine, the expansion of healthcare infrastructure in emerging markets, a higher number of clinical trials, improved reimbursement policies, increased investment in research and development for rare diseases, and rising diagnosis rates through genetic testing. Key trends in the forecast period include innovations in diagnostic technologies, advancements in drug delivery technology, progress in biomarker identification, the use of artificial intelligence in drug discovery, the development of next-generation sequencing technologies, and the creation of targeted gene therapies.

The growing emphasis on pediatric epilepsy is expected to significantly boost the growth of the Lennox-Gastaut syndrome drug market in the coming years. Pediatric epilepsy is a neurological condition marked by recurrent seizures in children, with its prevalence rising due to the increasing rates of neonatal and infant brain injuries, which can lead to the onset of epilepsy in early childhood. The focus on pediatric epilepsy reinforces the need for Lennox-Gastaut syndrome drugs by highlighting the importance of early intervention, as specialized medications are essential for managing hard-to-control seizures and preventing developmental delays in children with epilepsy. This underscores the demand for therapies tailored to address their specific neurological needs. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2021 and 2022, accounting for about 1% of the adult population in the United States. As a result, the rising attention on pediatric epilepsy is fueling the growth of the Lennox-Gastaut syndrome drug market.

Key players in the Lennox-Gastaut syndrome drug market are increasingly focusing on advancements in orphan drug designation to gain regulatory support, ensure market exclusivity, and expedite the commercialization of treatments for this rare and severe condition. Orphan drug designation is a special status granted by regulatory bodies, such as the FDA, to drugs developed for rare diseases or conditions that affect fewer than 200,000 individuals in a specific region. For example, in March 2023, Marinus Pharmaceuticals Inc., a U.S.-based pharmaceutical company, announced that the FDA had granted Orphan Drug Designation (ODD) to ganaxolone for treating Lennox-Gastaut syndrome (LGS). LGS is a severe form of epilepsy that begins in childhood and is marked by intractable seizures and neurodevelopmental impairment. This designation offers advantages including market exclusivity after regulatory approval, exemption from FDA application fees, and tax credits for eligible clinical trials.

In December 2024, H. Lundbeck A/S, a pharmaceutical company based in Denmark, acquired Longboard Pharmaceuticals for $2.6 billion. This acquisition expands Lundbeck's neurology and psychiatry portfolio by incorporating Longboard's promising pipeline of treatments for neurological diseases, including rare and orphan conditions. The move strengthens Lundbeck's position in the global market and enhances its research and development capabilities for central nervous system disorders. Longboard Pharmaceuticals Inc., a U.S.-based clinical-stage biopharmaceutical company, specializes in developing innovative, transformative medicines for Lennox-Gastaut syndrome.

Major players in the lennox-gastaut syndrome drug market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi SA, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, UCB SA, Eisai Co. Ltd., Amneal Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., Lundbeck A/S, GW Pharmaceuticals Plc, Ultragenyx Pharmaceutical Inc., Marinus Pharmaceuticals Inc., Stoke Therapeutics Inc., Zynerba Pharmaceuticals Inc., and Ovid Therapeutics Inc.

North America was the largest region in the lennox-gastaut syndrome drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lennox-gastaut syndrome drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lennox-gastaut syndrome drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lennox-gastaut syndrome (LGS) drug market consists of sales of corticosteroids, benzodiazepines, and sleep-inducing agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lennox-Gastaut Syndrome Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lennox-gastaut syndrome drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for lennox-gastaut syndrome drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lennox-gastaut syndrome drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Lennox-Gastaut Syndrome Drug Market Characteristics

3. Lennox-Gastaut Syndrome Drug Market Trends And Strategies

4. Lennox-Gastaut Syndrome Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lennox-Gastaut Syndrome Drug Growth Analysis And Strategic Analysis Framework

6. Lennox-Gastaut Syndrome Drug Market Segmentation

7. Lennox-Gastaut Syndrome Drug Market Regional And Country Analysis

8. Asia-Pacific Lennox-Gastaut Syndrome Drug Market

9. China Lennox-Gastaut Syndrome Drug Market

10. India Lennox-Gastaut Syndrome Drug Market

11. Japan Lennox-Gastaut Syndrome Drug Market

12. Australia Lennox-Gastaut Syndrome Drug Market

13. Indonesia Lennox-Gastaut Syndrome Drug Market

14. South Korea Lennox-Gastaut Syndrome Drug Market

15. Western Europe Lennox-Gastaut Syndrome Drug Market

16. UK Lennox-Gastaut Syndrome Drug Market

17. Germany Lennox-Gastaut Syndrome Drug Market

18. France Lennox-Gastaut Syndrome Drug Market

19. Italy Lennox-Gastaut Syndrome Drug Market

20. Spain Lennox-Gastaut Syndrome Drug Market

21. Eastern Europe Lennox-Gastaut Syndrome Drug Market

22. Russia Lennox-Gastaut Syndrome Drug Market

23. North America Lennox-Gastaut Syndrome Drug Market

24. USA Lennox-Gastaut Syndrome Drug Market

25. Canada Lennox-Gastaut Syndrome Drug Market

26. South America Lennox-Gastaut Syndrome Drug Market

27. Brazil Lennox-Gastaut Syndrome Drug Market

28. Middle East Lennox-Gastaut Syndrome Drug Market

29. Africa Lennox-Gastaut Syndrome Drug Market

30. Lennox-Gastaut Syndrome Drug Market Competitive Landscape And Company Profiles

31. Lennox-Gastaut Syndrome Drug Market Other Major And Innovative Companies

32. Global Lennox-Gastaut Syndrome Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lennox-Gastaut Syndrome Drug Market

34. Recent Developments In The Lennox-Gastaut Syndrome Drug Market

35. Lennox-Gastaut Syndrome Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â